NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal EpilepsyGlobeNewsWire • Monday
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?Zacks Investment Research • 10/28/24
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024GlobeNewsWire • 10/22/24
NeuroPace Announces Participation at Two Upcoming Healthcare Investor ConferencesGlobeNewsWire • 08/27/24
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/08/24
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024GlobeNewsWire • 02/15/24
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business UpdatesGlobeNewsWire • 01/08/24
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal StudyGlobeNewsWire • 12/21/23
NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking CollaborationGlobeNewsWire • 12/04/23
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual MeetingGlobeNewsWire • 12/01/23